Better Therapeutics, Inc.

Better Therapeutics, Inc. is the target company behind the de-SPAC transaction involving Mountain Crest Acquisition Corp. II, which traded under the ticker MCAD and was sponsored by Mountain Crest Capital LLC. The SPAC completed its initial public offering in 2021, targeting the healthcare and digital therapeutics sector. Better Therapeutics develops prescription digital therapeutics focused on cardiometabolic disease management. The 10-Q filed with the SEC on August 20, 2021, under accession number 0001104659-21-107860, represents a quarterly disclosure submitted during the active de-SPAC process. The combined company subsequently traded under the ticker BTTX following deal closure. Sign up at SpacDesk for full filing history, deal timelines, and sponsor analytics on this transaction and hundreds more.